$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418016468 Filed on March 22, 2018

Income Statement

Concept	2018 Q1	2017	2016 Q4
Revenue	$400.1K	$2.666M	$910.0K
YoY Change		-33.32%	-18.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.390M	$4.760M	$1.150M
YoY Change	16.81%	-3.45%	6.48%
% of Gross Profit
Research & Development	$2.697M	$10.77M	$2.670M
YoY Change	-17.28%	-32.89%	-19.82%
% of Gross Profit
Depreciation & Amortization	$34.06K	$144.2K	$40.00K
YoY Change	-12.15%	14.68%	33.33%
% of Gross Profit
Operating Expenses	$4.086M	$15.53M	$3.820M
YoY Change	-8.17%	-25.97%	-13.38%
Operating Profit	-$3.686M	-$12.86M
YoY Change		-24.23%
Interest Expense	$0.00	$398.8K	-$100.0K
YoY Change	-100.0%	15.71%	66.67%
% of Operating Profit
Other Income/Expense, Net	$14.65K	$15.29M
YoY Change		-935.61%
Pretax Income	-$3.670M	$2.430M	-$4.520M
YoY Change	0.0%	-112.92%	34.93%
Income Tax
% Of Pretax Income
Net Earnings	-$3.672M	$2.431M	-$4.520M
YoY Change	0.04%	-112.93%	34.93%
Net Earnings / Revenue	-917.73%	91.19%	-496.7%
Basic Earnings Per Share		$0.10
Diluted Earnings Per Share	-$1.364M	$0.09	-$2.112M
COMMON SHARES
Basic Shares Outstanding	27.71M shares	23.19M	21.40M shares
Diluted Shares Outstanding		26.79M

Balance Sheet

Concept	2018 Q1	2017	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.16M	$14.12M	$16.19M
YoY Change	12.1%	-12.79%	19.37%
Cash & Equivalents	$7.169M	$6.140M	$3.204M
Short-Term Investments	$5.995M	$7.980M	$12.99M
Other Short-Term Assets	$1.140M	$1.240M	$1.690M
YoY Change	-25.49%	-26.63%	704.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.61M	$15.71M	$18.11M
YoY Change	8.54%	-13.25%	29.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$540.0K	$370.0K	$435.3K
YoY Change	31.71%	-15.91%	36.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.0K	$100.0K	$60.00K
YoY Change	166.67%	66.67%	-14.29%
Total Long-Term Assets	$780.0K	$560.0K	$639.0K
YoY Change	28.28%	-12.5%	-69.27%
TOTAL ASSETS
Total Short-Term Assets	$14.61M	$15.71M	$18.11M
Total Long-Term Assets	$780.0K	$560.0K	$639.0K
Total Assets	$15.39M	$16.27M	$18.75M
YoY Change	9.4%	-13.23%	16.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.480M	$1.670M	$3.530M
YoY Change	-43.51%	-52.69%	22.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.480M	$1.670M	$4.895M
YoY Change	-55.14%	-65.92%	-25.02%
LONG-TERM LIABILITIES
Long-Term Debt	$3.380M	$3.380M	$17.01M
YoY Change	-80.13%	-80.13%	85.7%
Other Long-Term Liabilities		$0.00	$850.0K
YoY Change		-100.0%	-40.14%
Total Long-Term Liabilities	$3.380M	$3.380M	$17.86M
YoY Change	-81.18%	-81.08%	68.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.480M	$1.670M	$4.895M
Total Long-Term Liabilities	$3.380M	$3.380M	$17.86M
Total Liabilities	$4.850M	$5.050M	$22.75M
YoY Change	-77.19%	-77.8%	33.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.22M		-$53.98M
YoY Change	-4.21%		53.47%
Common Stock	$27.97K		$49.97M
YoY Change	-99.94%		46.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.53M	$11.23M	-$4.003M
YoY Change
Total Liabilities & Shareholders Equity	$15.39M	$16.27M	$18.75M
YoY Change	9.4%	-13.23%	16.66%

Cashflow Statement

Concept	2018 Q1	2017	2016 Q4
OPERATING ACTIVITIES
Net Income	-$3.672M	$2.431M	-$4.520M
YoY Change	0.04%	-112.93%	34.93%
Depreciation, Depletion And Amortization	$34.06K	$144.2K	$40.00K
YoY Change	-12.15%	14.68%	33.33%
Cash From Operating Activities	-$3.418M	-$14.23M	-$3.470M
YoY Change	-26.91%	-1.55%	-4.93%
INVESTING ACTIVITIES
Capital Expenditures	$186.4K	$32.19K	-$100.0K
YoY Change	5862.44%	-83.23%
Acquisitions
YoY Change
Other Investing Activities	$2.000M	$5.010M	-$10.49M
YoY Change	-50.0%	-200.2%	-309.8%
Cash From Investing Activities	$1.812M	$4.982M	-$10.59M
YoY Change	-54.71%	-195.96%	-312.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.373M	$11.07M
YoY Change		-20.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.513M	11.58M	0.000
YoY Change		-37.84%
NET CHANGE
Cash From Operating Activities	-3.418M	-14.23M	-3.470M
Cash From Investing Activities	1.812M	4.982M	-10.59M
Cash From Financing Activities	2.513M	11.58M	0.000
Net Change In Cash	906.6K	2.331M	-14.06M
YoY Change	-234.24%	-329.22%	-1149.25%
FREE CASH FLOW
Cash From Operating Activities	-$3.418M	-$14.23M	-$3.470M
Capital Expenditures	$186.4K	$32.19K	-$100.0K
Free Cash Flow	-$3.604M	-$14.26M	-$3.370M
YoY Change	-22.97%	-2.62%	-7.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	9560482	USD
CY2017	dei	Trading Symbol TradingSymbol	CAPR
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27712158	shares
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6140135	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3204378	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12990510	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7984800	USD
CY2017Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2016Q1	capr	Warrant Redemption Weighted Average Common Stock Per Share Threshold Limit WarrantRedemptionWeightedAverageCommonStockPerShareThresholdLimit	7.50
CY2016Q1	capr	Warrant Redemption Fees Per Share WarrantRedemptionFeesPerShare	0.001
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4895183	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1670675	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	13905857	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	USD
CY2016Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	849469	USD
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	17855326	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3376259	USD
CY2016Q4	us-gaap	Liabilities Liabilities	22750509	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5046934	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	49951165	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	62736783	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3524	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11620	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-4003154	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11226855	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18747355	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16273789	USD
CY2017Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	3376259	USD
CY2016Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	3100000	USD
CY2017	capr	Collaboration Revenue CollaborationRevenue	1367186	USD
CY2016	capr	Collaboration Revenue CollaborationRevenue	3190106	USD
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	808512	USD
CY2017	us-gaap	Revenue From Grants RevenueFromGrants	1115430	USD
CY2016	us-gaap	Revenues Revenues	3998618	USD
CY2017	us-gaap	Revenues Revenues	2666340	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16042082	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10766095	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4933054	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4762642	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	20975136	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	15528737	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-16976518	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-12862397	USD
CY2016	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	14407	USD
CY2017	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	38494	USD
CY2016	us-gaap	Interest Expense InterestExpense	344665	USD
CY2017	us-gaap	Interest Expense InterestExpense	398807	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1830258	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15293820	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-18806776	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	2431423	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5861	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8096	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18812637	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2439519	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1500000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13864817	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1962465	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11073152	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6640	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1710698	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	125719	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	144174	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1962465	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1710698	USD
CY2016	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	11397	USD
CY2017	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	121240	USD
CY2016	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	132289	USD
CY2017	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	158272	USD
CY2016	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-8720	USD
CY2017	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	34543	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	508280	USD
CY2017	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1542073	USD
CY2016	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	136883	USD
CY2017	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-314793	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	344106	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	398807	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3190106	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1367186	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14454395	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14230879	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17997361	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18986194	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13000000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24000000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	191970	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32185	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5191100	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4981621	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18628792	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11579792	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	1343	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6640	USD
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	13975	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4750000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	500000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	276259	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3100000	USD
CY2017	us-gaap	Depreciation Depreciation	94968	USD
CY2016	us-gaap	Depreciation Depreciation	85888	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	341650	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	250677	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49206	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11073152	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13864817	USD
CY2017	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	0	USD
CY2016	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	1769	USD
CY2017Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	14100000	USD
CY2016Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	16200000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	142031	USD
CY2017Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	14500000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17957	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.83
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2400000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	117849	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	223335	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1367186	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	26271	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	21399	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	147429	USD
CY2017	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	184000	USD
CY2017	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2017Q4	capr	Attorney And Filing Fee Payable AttorneyAndFilingFeePayable	50000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	431014	USD
CY2016Q4	capr	Disbursement Amount Under Grant Award DisbursementAmountUnderGrantAward	1100000	USD
CY2017Q4	capr	Disbursement Amount Under Grant Award DisbursementAmountUnderGrantAward	300000	USD
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6873903	shares
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y2M16D
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.62
CY2017Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	344575	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5836334	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y9M22D
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.30
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26270491	shares
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	166634	USD
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26270491	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21399019	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21399019	shares
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	183724	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2017Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	4.01
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5568306	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6882137	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18551013	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23193278	shares
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26788076	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18551013	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1081716	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1081903	shares
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13975	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-1031774	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2330534	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1016703	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4551603	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	12500	shares
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	713746	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	686013	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	43277	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	43276	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4330	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2165	USD
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3594798	shares
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	7984800	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	12990510	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1300000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48749	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	235830	shares
CY2016	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	846073	shares
CY2017	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	187	shares
CY2015Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	2.27
CY2016Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	4.01
CY2016	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	4.50
CY2017	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	2.27
CY2016	capr	Loan Payable Forgiven LoanPayableForgiven	0	USD
CY2017	capr	Payments For Reimbursement For Research And Development Expenses Incurred Related Party PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty	900000	USD
CY2016	capr	Payments For Reimbursement For Research And Development Expenses Incurred Related Party PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty	500000	USD
CY2017	capr	Loan Payable Forgiven LoanPayableForgiven	15654133	USD
CY2017Q4	us-gaap	Due From Related Parties DueFromRelatedParties	2100000	USD
CY2017Q4	capr	Amount Available Under Grant And Loan Awards AmountAvailableUnderGrantAndLoanAwards	5200000	USD

Files In Submission

Name	View Source	Status
0001144204-18-016468-index-headers.html	Edgar Link	pending
0001144204-18-016468-index.html	Edgar Link	pending
0001144204-18-016468.txt	Edgar Link	pending
0001144204-18-016468-xbrl.zip	Edgar Link	pending
capr-20171231.xml	Edgar Link	completed
capr-20171231.xsd	Edgar Link	pending
capr-20171231_cal.xml	Edgar Link	unprocessable
capr-20171231_def.xml	Edgar Link	unprocessable
capr-20171231_lab.xml	Edgar Link	unprocessable
capr-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487725_10k.htm	Edgar Link	pending
tv487725_ex10-58.htm	Edgar Link	pending
tv487725_ex10-59.htm	Edgar Link	pending
tv487725_ex21-1.htm	Edgar Link	pending
tv487725_ex23-1.htm	Edgar Link	pending
tv487725_ex31-1.htm	Edgar Link	pending
tv487725_ex31-2.htm	Edgar Link	pending
tv487725_ex32-1.htm	Edgar Link	pending
tv487725_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2018 Q1 Form 10-K Financial Statement

#000114420418016468 Filed on March 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2018 Q1 Form 10-K Financial Statement

#000114420418016468 Filed on March 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr